Arcturus Therapeutics Kicks Off Trial of Potential COVID-19 Vaccine

San Diego-based Arcturus Therapeutics has begun a phase 1/2 trial of its COVID-19 vaccine candidate ARCT-021 in collaboration with Duke-NUS Medical School in Singapore.

In the phase 1 portion, escalating doses will be administered as a single injection in adults aged 21 to 55 years old. Phase 2 will include a cohort of adults aged 56 to 80 years old.

ARCT-021 generated neutralizing antibodies against the SARS-CoV-2 coronavirus after a single 2-mcg dose in preclinical studies.